Surge in Drug Prices Tied to Revenue, Million-Dollar Bonuses

(Bloomberg) -- U.S. lawmakers took aim at drugmaker Celgene for continually boosting the price of the cancer drug Revlimid at the start of a two-day hearing on Wednesday, saying in some cases the m...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.